Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Patrick Thornton et al.|New England Journal of Medicine|2014Cited by 1.6k
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Michael Dickinson et al.|Nature Medicine|2021Cited by 523
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Nirav N. Shah et al.|The Lancet|2021Cited by 456
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E. Budde, Nancy L. Bartlett, Laurie H. Sehn et al.|The Lancet Oncology|2022Cited by 429
An NK-like CAR T cell transition in CAR T cell dysfunctionCharly R. Good, Carl H. June, M. Ángela Aznar et al.|Cell|2021Cited by 398